Comparative proteomic analysis for the insoluble fractions of colorectal cancer patients

Journal of Proteomics

Volumn 75, Issue 12, 2012, Pages 3639-3653

  Yang, Hee Young ^a   Kwon, Joseph ^b   Park, Hyang Rim ^a   Kwon, Sang Oh ^b   Park, Young Kyu ^a   Kim, Hyung Seok ^c   Chung, Yun Jo ^d   Chang, Yu Jung ^d   Choi, Hoon In ^a   Chung, Kyoung Jin ^a   Lee, Dong Seok ^e   Park, Byung Ju ^a   Jeong, Sang Hun ^b   Lee, Tae Hoon ^a  

^a Chonnam National University   (South Korea)

^b Korea Basic Science Institute (KBSI)   (South Korea)

^c Chonnam National University Medical School   (South Korea)

^d Chonbuk National University   (South Korea)

^e Kyungpook National University   (South Korea)

Author keywords

Biomarker; Colorectal cancer; Cytoskeleton; Insoluble fraction; Nano UPLC MS E

Indexed keywords

ACTIN; BIOLOGICAL MARKER; COLLAGEN; KERATIN; LUMICAN; MYOSIN; TRANSCRIPTION FACTOR RUNX2; TUBULIN; VITRONECTIN;

ADULT; AGED; ARTICLE; ASCENDING COLON; BONE DISEASE; CANCER INCIDENCE; CANCER PATIENT; CANCER STAGING; CANCER TISSUE; CLINICAL ARTICLE; COLORECTAL CANCER; DESCENDING COLON; FEMALE; GENETIC DISORDER; HUMAN; HUMAN TISSUE; MALE; MUSCLE DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RECTUM; SIGMOID; TRANSVERSE COLON; TUMOR BIOPSY; WESTERN BLOTTING;

ADULT; AGED; COLORECTAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROTEOME; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOLUBILITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84862169998     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.04.018     Document Type: Article

References (59)

1. Liotta L.A., Kohn E.C., Petricoin E.F. Clinical proteomics: personalized molecular medicine. JAMA 2001, 286:2211-2214.
2. Albrethsen J., Knol J.C., Piersma S.R., Pham T.V., de Wit M., Mongera S., et al. Subnuclear proteomics in colorectal cancer: identification of proteins enriched in the nuclear matrix fraction and regulation in adenoma to carcinoma progression. Mol Cell Proteomics 2010, 9:988-1005.
3. Yates J.R., Gilchrist A., Howell K.E., Bergeron J.J. Proteomics of organelles and large cellular structures. Nat Rev Mol Cell Biol 2005, 6:702-714.
4. Cox B., Emili A. Tissue subcellular fractionation and protein extraction for use in mass-spectrometry-based proteomics. Nat Protoc 2006, 1:1872-1878.
5. Weitz J., Koch M., Debus J., Hohler T., Galle P.R., Buchler M.W. Colorectal cancer. Lancet 2005, 365:153-165.
6. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002, 2:210-219.
7. Alessandro R., Belluco C., Kohn E.C. Proteomic approaches in colon cancer: promising tools for new cancer markers and drug target discovery. Clin Colorectal Cancer 2005, 4:396-402.
8. Fuchs E., Cleveland D.W. A structural scaffolding of intermediate filaments in health and disease. Science 1998, 279:514-519.
9. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998, 279:509-514.
10. Gupton S.L., Gertler F.B. Filopodia: the fingers that do the walking. Science's STKE : signal transduction knowledge environment 2007, 2007:re5.
11. Pollard T.D., Borisy G.G. Cellular motility driven by assembly and disassembly of actin filaments. Cell 2003, 112:453-465.
12. Ridley A.J., Schwartz M.A., Burridge K., Firtel R.A., Ginsberg M.H., Borisy G., et al. Cell migration: integrating signals from front to back. Science 2003, 302:1704-1709.
13. Small J.V., Stradal T., Vignal E., Rottner K. The lamellipodium: where motility begins. Trends Cell Biol 2002, 12:112-120.
14. Wang Y., Kelber J.A., Tran Cao H.S., Cantin G.T., Lin R., Wang W., et al. Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression [corrected]. Proc Natl Acad Sci U S A 2010, 107:10920-10925.
15. Buda A., Pignatelli M. Cytoskeletal network in colon cancer: from genes to clinical application. Int J Biochem Cell Biol 2004, 36:759-765.
16. Luber B., Candidus S., Handschuh G., Mentele E., Hutzler P., Feller S., et al. Tumor-derived mutated E-cadherin influences beta-catenin localization and increases susceptibility to actin cytoskeletal changes induced by pervanadate. Cell Adhes Commun 2000, 7:391-408.
17. Kumar R. Commentary: targeting colorectal cancer through molecular biology. Semin Oncol 2005, 32:S37-S39.
18. Nathke I. Relationship between the role of the adenomatous polyposis coli protein in colon cancer and its contribution to cytoskeletal regulation. Biochem Soc Trans 2005, 33:694-697.
19. Yang H.Y., Kwon J., Cho E.J., Choi H.I., Park C., Park H.R., et al. Proteomic analysis of protein expression affected by peroxiredoxin V knock-down in hypoxic kidney. J Proteome Res 2010, 9:4003-4015.
20. Kim S., Kang H.Y., Nam E.H., Choi M.S., Zhao X.F., Hong C.S., et al. TMPRSS4 induces invasion and epithelial-mesenchymal transition through upregulation of integrin alpha5 and its signaling pathways. Carcinogenesis 2010, 31:597-606.
21. Swanton C., Tomlinson I., Downward J. Chromosomal instability, colorectal cancer and taxane resistance. Cell Cycle 2006, 5:818-823.
22. Dumontet C., Jordan M.A., Lee F.F. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 2009, 8:17-25.
23. Kavallaris M., Kuo D.Y., Burkhart C.A., Regl D.L., Norris M.D., Haber M., et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997, 100:1282-1293.
24. Mozzetti S., Ferlini C., Concolino P., Filippetti F., Raspaglio G., Prislei S., et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005, 11:298-305.
25. Lee F.Y., Borzilleri R., Fairchild C.R., Kim S.H., Long B.H., Reventos-Suarez C., et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001, 7:1429-1437.
26. Fumoleau P., Coudert B., Isambert N., Ferrant E. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol 2007, 18(Suppl. 5):v9-v15.
27. Carragher N.O., Frame M.C. Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. Trends Cell Biol 2004, 14:241-249.
28. Guo W., Giancotti F.G. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004, 5:816-826.
29. Klein-Scory S., Kubler S., Diehl H., Eilert-Micus C., Reinacher-Schick A., Stuhler K., et al. Immunoscreening of the extracellular proteome of colorectal cancer cells. BMC Cancer 2010, 10:70.
30. Hardouin J., Lasserre J.P., Sylvius L., Joubert-Caron R., Caron M. Cancer immunomics: from serological proteome analysis to multiple affinity protein profiling. Ann N Y Acad Sci 2007, 1107:223-230.
31. Diehl H.C., Stuhler K., Klein-Scory S., Volmer M.W., Schoneck A., Bieling C., et al. A catalogue of proteins released by colorectal cancer cells in vitro as an alternative source for biomarker discovery. Proteomics Clin Appl 2007, 1:47-61.
32. Volmer M.W., Stuhler K., Zapatka M., Schoneck A., Klein-Scory S., Schmiegel W., et al. Differential proteome analysis of conditioned media to detect Smad4 regulated secreted biomarkers in colon cancer. Proteomics 2005, 5:2587-2601.
33. Wu C.C., Chen H.C., Chen S.J., Liu H.P., Hsieh Y.Y., Yu C.J., et al. Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics 2008, 8:316-332.
34. Olver C., Vidal M. Proteomic analysis of secreted exosomes. Subcell Biochem 2007, 43:99-131.
35. Kim H.J., Kang H.J., Lee H., Lee S.T., Yu M.H., Kim H., et al. Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J Proteome Res 2009, 8:1368-1379.
36. Xue H., Lu B., Zhang J., Wu M., Huang Q., Wu Q., et al. Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J Proteome Res 2010, 9:545-555.
37. Chiu K.H., Chang Y.H., Wu Y.S., Lee S.H., Liao P.C. Quantitative secretome analysis reveals that COL6A1 is a metastasis-associated protein using stacking gel-aided purification combined with iTRAQ labeling. J Proteome Res 2011, 10:1110-1125.
38. Madoz-Gurpide J., Canamero M., Sanchez L., Solano J., Alfonso P., Casal J.I. A proteomics analysis of cell signaling alterations in colorectal cancer. Mol Cell Proteomics 2007, 6:2150-2164.
39. Chen J.S., Chen K.T., Fan C.W., Han C.L., Chen Y.J., Yu J.S., et al. Comparison of membrane fraction proteomic profiles of normal and cancerous human colorectal tissues with gel-assisted digestion and iTRAQ labeling mass spectrometry. FEBS J 2010, 277:3028-3038.
40. Ma Y., Peng J., Liu W., Zhang P., Huang L., Gao B., et al. Proteomics identification of desmin as a potential oncofetal diagnostic and prognostic biomarker in colorectal cancer. Mol Cell Proteomics 2009, 8:1878-1890.
41. Nibbe R.K., Markowitz S., Myeroff L., Ewing R., Chance M.R. Discovery and scoring of protein interaction subnetworks discriminative of late stage human colon cancer. Mol Cell Proteomics 2009, 8:827-845.
42. Moll R., Divo M., Langbein L. The human keratins: biology and pathology. Histochem Cell Biol 2008, 129:705-733.
43. Karantza V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene 2011, 30:127-138.
44. Casanova M.L., Bravo A., Ramirez A., Morreale de Escobar G., Were F., Merlino G. Exocrine pancreatic disorders in transsgenic mice expressing human keratin 8. J Clin Invest 1999, 103:1587-1595.
45. Toivola D.M., Nakamichi I., Strnad P., Michie S.A., Ghori N., Harada M., et al. Keratin overexpression levels correlate with the extent of spontaneous pancreatic injury. Am J Pathol 2008, 172:882-892.
46. Casanova M.L., Bravo A., Martinez-Palacio J., Fernandez-Acenero M.J., Villanueva C., Larcher F., et al. Epidermal abnormalities and increased malignancy of skin tumors in human epidermal keratin 8-expressing transgenic mice. FASEB J 2004, 18:1556-1558.
47. Lee W.S., Seo G., Shin H.J., Yun S.H., Yun H., Choi N., et al. Identification of differentially expressed genes in microsatellite stable HNPCC and sporadic colon cancer. J Surg Res 2008, 144:29-35.
48. Gorgens H., Kruger S., Kuhlisch E., Pagenstecher C., Hohl R., Schackert H.K., et al. Microsatellite stable colorectal cancers in clinically suspected hereditary nonpolyposis colorectal cancer patients without vertical transmission of disease are unlikely to be caused by biallelic germline mutations in MYH. J Mol Diagn 2006, 8:178-182.
49. Camilo R., Capelozzi V.L., Siqueira S.A., Del Carlo Bernardi F. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum Pathol 2006, 37:542-546.
50. Carella R., Deleonardi G., D'Errico A., Salerno A., Egarter-Vigl E., Seebacher C., et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol 2001, 25:43-50.
51. Jerome Marson V., Mazieres J., Groussard O., Garcia O., Berjaud J., Dahan M., et al. Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours: correlation with histological type and grade. Histopathology 2004, 45:125-134.
52. Gastaldi T., Bonvini P., Sartori F., Marrone A., Iolascon A., Rosolen A. Plakoglobin is differentially expressed in alveolar and embryonal rhabdomyosarcoma and is regulated by DNA methylation and histone acetylation. Carcinogenesis 2006, 27:1758-1767.
53. Ghadimi B.M., Behrens J., Hoffmann I., Haensch W., Birchmeier W., Schlag P.M. Immunohistological analysis of E-cadherin, alpha-, beta- and gamma-catenin expression in colorectal cancer: implications for cell adhesion and signaling. Eur J Cancer 1999, 35:60-65.
54. Luque-Garcia J.L., Martinez-Torrecuadrada J.L., Epifano C., Canamero M., Babel I., Casal J.I. Differential protein expression on the cell surface of colorectal cancer cells associated to tumor metastasis. Proteomics 2010, 10:940-952.
55. Bondi J., Bukholm G., Nesland J.M., Bukholm I.R. Expression of non-membranous beta-catenin and gamma-catenin, c-Myc and cyclin D1 in relation to patient outcome in human colon adenocarcinomas. APMIS 2004, 112:49-56.
56. Nagel J.M., Kriegl L., Horst D., Engel J., Gautam S., Mantzoros C.S., et al. gamma-Catenin is an independent prognostic marker in early stage colorectal cancer. Int J Colorectal Dis 2010, 25:1301-1309.
57. Saint-Guirons J., Zeqiraj E., Schumacher U., Greenwell P., Dwek M. Proteome analysis of metastatic colorectal cancer cells recognized by the lectin Helix pomatia agglutinin (HPA). Proteomics 2007, 7:4082-4089.
58. Barderas R., Babel I., Casal J.I. Colorectal cancer proteomics, molecular characterization and biomarker discovery. Proteomics Clin Appl 2010, 4:159-178.
59. Li Y., Liang Q., Wen Y.Q., Chen L.L., Wang L.T., Liu Y.L., et al. Comparative proteomics analysis of human osteosarcomas and benign tumor of bone. Cancer Genet Cytogenet 2010, 198:97-106.